ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Primary Sclerosing Cholangitis Treatment Market Insights, Forecast to 2030
Published Date: December 2024
|
Report Code: QYRE-Auto-10N3048
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Primary Sclerosing Cholangitis Treatment Market Insights Forecast to 2028
BUY CHAPTERS

Global Primary Sclerosing Cholangitis Treatment Market Insights, Forecast to 2030

Code: QYRE-Auto-10N3048
Report
December 2024
Pages:129
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Allergan plc
Glenmark
Impax Laboratories
Mylan NV
Teva Pharmaceuticals
Dr. Falk Pharma
Daewoong Pharmaceutical
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Bruschettini
Shanghai Pharma
Grindeks
Acorda Therapeutics
Gilead Sciences
Intercept Pharmaceuticals
Shire Plc
NGM Biopharmaceuticals
Conatus Pharmaceuticals
DURECT Corporation
Sirnaomics
Shenzhen HighTide Biopharmaceuticals

Primary Sclerosing Cholangitis Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Primary Sclerosing Cholangitis Treatment Market

Primary Sclerosing Cholangitis Treatment Market

Primary sclerosing cholangitis is a chronic liver disease that may occur alone or be caused by other diseases.The disease is characterized by inflammation and thickening of the bile ducts.This impedes bile flow and may lead to other liver diseases.Primary sclerosing cholangitis (PSC) is treated in addition to PSC and avoids other liver diseases.Available options are liver transplantation, UDCA drugs, and PSC drugs, each with advantages and disadvantages in cost and efficacy.
Market Analysis and Insights: Global Primary Sclerosing Cholangitis Treatment Market
The global Primary Sclerosing Cholangitis Treatment market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Primary Sclerosing Cholangitis Treatment market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Primary Sclerosing Cholangitis Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Primary Sclerosing Cholangitis Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Primary Sclerosing Cholangitis Treatment revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Primary Sclerosing Cholangitis Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Primary Sclerosing Cholangitis Treatment revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation

Scope of Primary Sclerosing Cholangitis Treatment Market Report

Report Metric Details
Report Name Primary Sclerosing Cholangitis Treatment Market
CAGR 5%
Segment by Type
Segment by Application
  • Hospital
  • Clinics
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Allergan, Glenmark, Impax Laboratories, Mylan, Teva Pharmaceuticals, Dr. Falk Pharma, Daewoong Pharmaceutical, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Bruschettini, Shanghai Pharma, Grindeks, Acorda Therapeutics, Gilead Sciences, Intercept Pharmaceuticals, Shire Plc, NGM Biopharmaceuticals, Conatus Pharmaceuticals, Durect Corporation, Sirnaomics, Shenzhen HighTide Biopharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Revenue of Primary Sclerosing Cholangitis Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Primary Sclerosing Cholangitis Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 8: China by Type, and by Application, revenue for each segment.
  • Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Primary Sclerosing Cholangitis Treatment revenue, gross margin, and recent development, etc.
  • Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

Who are the main players in the Primary Sclerosing Cholangitis Treatment Market report?

Ans: The main players in the Primary Sclerosing Cholangitis Treatment Market are Allergan, Glenmark, Impax Laboratories, Mylan, Teva Pharmaceuticals, Dr. Falk Pharma, Daewoong Pharmaceutical, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Bruschettini, Shanghai Pharma, Grindeks, Acorda Therapeutics, Gilead Sciences, Intercept Pharmaceuticals, Shire Plc, NGM Biopharmaceuticals, Conatus Pharmaceuticals, Durect Corporation, Sirnaomics, Shenzhen HighTide Biopharmaceuticals

What are the Application segmentation covered in the Primary Sclerosing Cholangitis Treatment Market report?

Ans: The Applications covered in the Primary Sclerosing Cholangitis Treatment Market report are Hospital, Clinics, Other

What are the Type segmentation covered in the Primary Sclerosing Cholangitis Treatment Market report?

Ans: The Types covered in the Primary Sclerosing Cholangitis Treatment Market report are Liver Transplantation Operation, UDCA Drugs, PSC Drugs

Recommended Reports

Liver Disease Therapies

Autoimmune & Inflammation

Digestive Disorders Care

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Liver Transplantation Operation
1.2.3 UDCA Drugs
1.2.4 PSC Drugs
1.3 Market by Application
1.3.1 Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Sclerosing Cholangitis Treatment Market Perspective (2019-2030)
2.2 Global Primary Sclerosing Cholangitis Treatment Growth Trends by Region
2.2.1 Primary Sclerosing Cholangitis Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Primary Sclerosing Cholangitis Treatment Historic Market Size by Region (2019-2024)
2.2.3 Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Region (2025-2030)
2.3 Primary Sclerosing Cholangitis Treatment Market Dynamics
2.3.1 Primary Sclerosing Cholangitis Treatment Industry Trends
2.3.2 Primary Sclerosing Cholangitis Treatment Market Drivers
2.3.3 Primary Sclerosing Cholangitis Treatment Market Challenges
2.3.4 Primary Sclerosing Cholangitis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Primary Sclerosing Cholangitis Treatment by Players
3.1.1 Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2019-2024)
3.1.2 Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Primary Sclerosing Cholangitis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Primary Sclerosing Cholangitis Treatment, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio
3.4.1 Global Primary Sclerosing Cholangitis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis Treatment Revenue in 2023
3.5 Global Key Players of Primary Sclerosing Cholangitis Treatment Head office and Area Served
3.6 Global Key Players of Primary Sclerosing Cholangitis Treatment, Product and Application
3.7 Global Key Players of Primary Sclerosing Cholangitis Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Sclerosing Cholangitis Treatment Breakdown Data by Type
4.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Type (2019-2024)
4.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2025-2030)
5 Primary Sclerosing Cholangitis Treatment Breakdown Data by Application
5.1 Global Primary Sclerosing Cholangitis Treatment Historic Market Size by Application (2019-2024)
5.2 Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
6.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Type
6.2.1 North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024)
6.2.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030)
6.2.3 North America Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
6.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Application
6.3.1 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024)
6.3.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030)
6.3.3 North America Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
6.4 North America Primary Sclerosing Cholangitis Treatment Market Size by Country
6.4.1 North America Primary Sclerosing Cholangitis Treatment Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024)
6.4.3 North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
7.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type
7.2.1 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024)
7.2.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030)
7.2.3 Europe Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
7.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application
7.3.1 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024)
7.3.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030)
7.3.3 Europe Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
7.4 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country
7.4.1 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024)
7.4.3 Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
8.2 China Primary Sclerosing Cholangitis Treatment Market Size by Type
8.2.1 China Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024)
8.2.2 China Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030)
8.2.3 China Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
8.3 China Primary Sclerosing Cholangitis Treatment Market Size by Application
8.3.1 China Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024)
8.3.2 China Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030)
8.3.3 China Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
9.2 Asia Primary Sclerosing Cholangitis Treatment Market Size by Type
9.2.1 Asia Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024)
9.2.2 Asia Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030)
9.2.3 Asia Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
9.3 Asia Primary Sclerosing Cholangitis Treatment Market Size by Application
9.3.1 Asia Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024)
9.3.2 Asia Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030)
9.3.3 Asia Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
9.4 Asia Primary Sclerosing Cholangitis Treatment Market Size by Region
9.4.1 Asia Primary Sclerosing Cholangitis Treatment Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Primary Sclerosing Cholangitis Treatment Market Size by Region (2019-2024)
9.4.3 Asia Primary Sclerosing Cholangitis Treatment Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Allergan
11.1.1 Allergan Company Details
11.1.2 Allergan Business Overview
11.1.3 Allergan Primary Sclerosing Cholangitis Treatment Introduction
11.1.4 Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.1.5 Allergan Recent Developments
11.2 Glenmark
11.2.1 Glenmark Company Details
11.2.2 Glenmark Business Overview
11.2.3 Glenmark Primary Sclerosing Cholangitis Treatment Introduction
11.2.4 Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.2.5 Glenmark Recent Developments
11.3 Impax Laboratories
11.3.1 Impax Laboratories Company Details
11.3.2 Impax Laboratories Business Overview
11.3.3 Impax Laboratories Primary Sclerosing Cholangitis Treatment Introduction
11.3.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.3.5 Impax Laboratories Recent Developments
11.4 Mylan
11.4.1 Mylan Company Details
11.4.2 Mylan Business Overview
11.4.3 Mylan Primary Sclerosing Cholangitis Treatment Introduction
11.4.4 Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.4.5 Mylan Recent Developments
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Details
11.5.2 Teva Pharmaceuticals Business Overview
11.5.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.5.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.5.5 Teva Pharmaceuticals Recent Developments
11.6 Dr. Falk Pharma
11.6.1 Dr. Falk Pharma Company Details
11.6.2 Dr. Falk Pharma Business Overview
11.6.3 Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.6.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.6.5 Dr. Falk Pharma Recent Developments
11.7 Daewoong Pharmaceutical
11.7.1 Daewoong Pharmaceutical Company Details
11.7.2 Daewoong Pharmaceutical Business Overview
11.7.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Introduction
11.7.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.7.5 Daewoong Pharmaceutical Recent Developments
11.8 Epic Pharma
11.8.1 Epic Pharma Company Details
11.8.2 Epic Pharma Business Overview
11.8.3 Epic Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.8.4 Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.8.5 Epic Pharma Recent Developments
11.9 Mitsubishi Tanabe Pharma
11.9.1 Mitsubishi Tanabe Pharma Company Details
11.9.2 Mitsubishi Tanabe Pharma Business Overview
11.9.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.9.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.9.5 Mitsubishi Tanabe Pharma Recent Developments
11.10 Lannett
11.10.1 Lannett Company Details
11.10.2 Lannett Business Overview
11.10.3 Lannett Primary Sclerosing Cholangitis Treatment Introduction
11.10.4 Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.10.5 Lannett Recent Developments
11.11 Bruschettini
11.11.1 Bruschettini Company Details
11.11.2 Bruschettini Business Overview
11.11.3 Bruschettini Primary Sclerosing Cholangitis Treatment Introduction
11.11.4 Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.11.5 Bruschettini Recent Developments
11.12 Shanghai Pharma
11.12.1 Shanghai Pharma Company Details
11.12.2 Shanghai Pharma Business Overview
11.12.3 Shanghai Pharma Primary Sclerosing Cholangitis Treatment Introduction
11.12.4 Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.12.5 Shanghai Pharma Recent Developments
11.13 Grindeks
11.13.1 Grindeks Company Details
11.13.2 Grindeks Business Overview
11.13.3 Grindeks Primary Sclerosing Cholangitis Treatment Introduction
11.13.4 Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.13.5 Grindeks Recent Developments
11.14 Acorda Therapeutics
11.14.1 Acorda Therapeutics Company Details
11.14.2 Acorda Therapeutics Business Overview
11.14.3 Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Introduction
11.14.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.14.5 Acorda Therapeutics Recent Developments
11.15 Gilead Sciences
11.15.1 Gilead Sciences Company Details
11.15.2 Gilead Sciences Business Overview
11.15.3 Gilead Sciences Primary Sclerosing Cholangitis Treatment Introduction
11.15.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.15.5 Gilead Sciences Recent Developments
11.16 Intercept Pharmaceuticals
11.16.1 Intercept Pharmaceuticals Company Details
11.16.2 Intercept Pharmaceuticals Business Overview
11.16.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.16.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.16.5 Intercept Pharmaceuticals Recent Developments
11.17 Shire Plc
11.17.1 Shire Plc Company Details
11.17.2 Shire Plc Business Overview
11.17.3 Shire Plc Primary Sclerosing Cholangitis Treatment Introduction
11.17.4 Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.17.5 Shire Plc Recent Developments
11.18 NGM Biopharmaceuticals
11.18.1 NGM Biopharmaceuticals Company Details
11.18.2 NGM Biopharmaceuticals Business Overview
11.18.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.18.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.18.5 NGM Biopharmaceuticals Recent Developments
11.19 Conatus Pharmaceuticals
11.19.1 Conatus Pharmaceuticals Company Details
11.19.2 Conatus Pharmaceuticals Business Overview
11.19.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.19.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.19.5 Conatus Pharmaceuticals Recent Developments
11.20 Durect Corporation
11.20.1 Durect Corporation Company Details
11.20.2 Durect Corporation Business Overview
11.20.3 Durect Corporation Primary Sclerosing Cholangitis Treatment Introduction
11.20.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.20.5 Durect Corporation Recent Developments
11.21 Sirnaomics
11.21.1 Sirnaomics Company Details
11.21.2 Sirnaomics Business Overview
11.21.3 Sirnaomics Primary Sclerosing Cholangitis Treatment Introduction
11.21.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.21.5 Sirnaomics Recent Developments
11.22 Shenzhen HighTide Biopharmaceuticals
11.22.1 Shenzhen HighTide Biopharmaceuticals Company Details
11.22.2 Shenzhen HighTide Biopharmaceuticals Business Overview
11.22.3 Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Introduction
11.22.4 Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
11.22.5 Shenzhen HighTide Biopharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Allergan plc
Glenmark
Impax Laboratories
Mylan NV
Teva Pharmaceuticals
Dr. Falk Pharma
Daewoong Pharmaceutical
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Bruschettini
Shanghai Pharma
Grindeks
Acorda Therapeutics
Gilead Sciences
Intercept Pharmaceuticals
Shire Plc
NGM Biopharmaceuticals
Conatus Pharmaceuticals
DURECT Corporation
Sirnaomics
Shenzhen HighTide Biopharmaceuticals
List of Tables
    Table 1. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Liver Transplantation Operation
    Table 3. Key Players of UDCA Drugs
    Table 4. Key Players of PSC Drugs
    Table 5. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 6. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Primary Sclerosing Cholangitis Treatment Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Primary Sclerosing Cholangitis Treatment Market Share by Region (2019-2024)
    Table 9. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Primary Sclerosing Cholangitis Treatment Market Share by Region (2025-2030)
    Table 11. Primary Sclerosing Cholangitis Treatment Market Trends
    Table 12. Primary Sclerosing Cholangitis Treatment Market Drivers
    Table 13. Primary Sclerosing Cholangitis Treatment Market Challenges
    Table 14. Primary Sclerosing Cholangitis Treatment Market Restraints
    Table 15. Global Primary Sclerosing Cholangitis Treatment Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Players (2019-2024)
    Table 17. Global Top Primary Sclerosing Cholangitis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2023)
    Table 18. Global Primary Sclerosing Cholangitis Treatment Industry Ranking 2022 VS 2023 VS 2024
    Table 19. Global 5 Largest Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Global Key Players of Primary Sclerosing Cholangitis Treatment, Headquarters and Area Served
    Table 21. Global Key Players of Primary Sclerosing Cholangitis Treatment, Product and Application
    Table 22. Global Key Players of Primary Sclerosing Cholangitis Treatment, Product and Application
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2019-2024)
    Table 26. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Primary Sclerosing Cholangitis Treatment Revenue Market Share by Type (2025-2030)
    Table 28. Global Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Application (2019-2024)
    Table 30. Global Primary Sclerosing Cholangitis Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Primary Sclerosing Cholangitis Treatment Revenue Share by Application (2025-2030)
    Table 32. North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 33. North America Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 34. North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 35. North America Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 36. North America Primary Sclerosing Cholangitis Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 38. North America Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 40. Europe Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 41. Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 42. Europe Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 43. Europe Primary Sclerosing Cholangitis Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Europe Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 46. China Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 47. China Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 48. China Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 49. China Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 50. Asia Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 51. Asia Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 52. Asia Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 53. Asia Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 54. Asia Primary Sclerosing Cholangitis Treatment Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 55. Asia Primary Sclerosing Cholangitis Treatment Market Size by Region (2019-2024) & (US$ Million)
    Table 56. Asia Primary Sclerosing Cholangitis Treatment Market Size by Region (2025-2030) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 62. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 64. Allergan Company Details
    Table 65. Allergan Business Overview
    Table 66. Allergan Primary Sclerosing Cholangitis Treatment Product
    Table 67. Allergan Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 68. Allergan Recent Developments
    Table 69. Glenmark Company Details
    Table 70. Glenmark Business Overview
    Table 71. Glenmark Primary Sclerosing Cholangitis Treatment Product
    Table 72. Glenmark Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 73. Glenmark Recent Developments
    Table 74. Impax Laboratories Company Details
    Table 75. Impax Laboratories Business Overview
    Table 76. Impax Laboratories Primary Sclerosing Cholangitis Treatment Product
    Table 77. Impax Laboratories Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 78. Impax Laboratories Recent Developments
    Table 79. Mylan Company Details
    Table 80. Mylan Business Overview
    Table 81. Mylan Primary Sclerosing Cholangitis Treatment Product
    Table 82. Mylan Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 83. Mylan Recent Developments
    Table 84. Teva Pharmaceuticals Company Details
    Table 85. Teva Pharmaceuticals Business Overview
    Table 86. Teva Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
    Table 87. Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 88. Teva Pharmaceuticals Recent Developments
    Table 89. Dr. Falk Pharma Company Details
    Table 90. Dr. Falk Pharma Business Overview
    Table 91. Dr. Falk Pharma Primary Sclerosing Cholangitis Treatment Product
    Table 92. Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 93. Dr. Falk Pharma Recent Developments
    Table 94. Daewoong Pharmaceutical Company Details
    Table 95. Daewoong Pharmaceutical Business Overview
    Table 96. Daewoong Pharmaceutical Primary Sclerosing Cholangitis Treatment Product
    Table 97. Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 98. Daewoong Pharmaceutical Recent Developments
    Table 99. Epic Pharma Company Details
    Table 100. Epic Pharma Business Overview
    Table 101. Epic Pharma Primary Sclerosing Cholangitis Treatment Product
    Table 102. Epic Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 103. Epic Pharma Recent Developments
    Table 104. Mitsubishi Tanabe Pharma Company Details
    Table 105. Mitsubishi Tanabe Pharma Business Overview
    Table 106. Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis Treatment Product
    Table 107. Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 108. Mitsubishi Tanabe Pharma Recent Developments
    Table 109. Lannett Company Details
    Table 110. Lannett Business Overview
    Table 111. Lannett Primary Sclerosing Cholangitis Treatment Product
    Table 112. Lannett Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 113. Lannett Recent Developments
    Table 114. Bruschettini Company Details
    Table 115. Bruschettini Business Overview
    Table 116. Bruschettini Primary Sclerosing Cholangitis Treatment Product
    Table 117. Bruschettini Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 118. Bruschettini Recent Developments
    Table 119. Shanghai Pharma Company Details
    Table 120. Shanghai Pharma Business Overview
    Table 121. Shanghai Pharma Primary Sclerosing Cholangitis Treatment Product
    Table 122. Shanghai Pharma Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 123. Shanghai Pharma Recent Developments
    Table 124. Grindeks Company Details
    Table 125. Grindeks Business Overview
    Table 126. Grindeks Primary Sclerosing Cholangitis Treatment Product
    Table 127. Grindeks Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 128. Grindeks Recent Developments
    Table 129. Acorda Therapeutics Company Details
    Table 130. Acorda Therapeutics Business Overview
    Table 131. Acorda Therapeutics Primary Sclerosing Cholangitis Treatment Product
    Table 132. Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 133. Acorda Therapeutics Recent Developments
    Table 134. Gilead Sciences Company Details
    Table 135. Gilead Sciences Business Overview
    Table 136. Gilead Sciences Primary Sclerosing Cholangitis Treatment Product
    Table 137. Gilead Sciences Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 138. Gilead Sciences Recent Developments
    Table 139. Intercept Pharmaceuticals Company Details
    Table 140. Intercept Pharmaceuticals Business Overview
    Table 141. Intercept Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
    Table 142. Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 143. Intercept Pharmaceuticals Recent Developments
    Table 144. Shire Plc Company Details
    Table 145. Shire Plc Business Overview
    Table 146. Shire Plc Primary Sclerosing Cholangitis Treatment Product
    Table 147. Shire Plc Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 148. Shire Plc Recent Developments
    Table 149. NGM Biopharmaceuticals Company Details
    Table 150. NGM Biopharmaceuticals Business Overview
    Table 151. NGM Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product
    Table 152. NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 153. NGM Biopharmaceuticals Recent Developments
    Table 154. Conatus Pharmaceuticals Company Details
    Table 155. Conatus Pharmaceuticals Business Overview
    Table 156. Conatus Pharmaceuticals Primary Sclerosing Cholangitis Treatment Product
    Table 157. Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 158. Conatus Pharmaceuticals Recent Developments
    Table 159. Durect Corporation Company Details
    Table 160. Durect Corporation Business Overview
    Table 161. Durect Corporation Primary Sclerosing Cholangitis Treatment Product
    Table 162. Durect Corporation Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 163. Durect Corporation Recent Developments
    Table 164. Sirnaomics Company Details
    Table 165. Sirnaomics Business Overview
    Table 166. Sirnaomics Primary Sclerosing Cholangitis Treatment Product
    Table 167. Sirnaomics Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 168. Sirnaomics Recent Developments
    Table 169. Shenzhen HighTide Biopharmaceuticals Company Details
    Table 170. Shenzhen HighTide Biopharmaceuticals Business Overview
    Table 171. Shenzhen HighTide Biopharmaceuticals Primary Sclerosing Cholangitis Treatment Product
    Table 172. Shenzhen HighTide Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis Treatment Business (2019-2024) & (US$ Million)
    Table 173. Shenzhen HighTide Biopharmaceuticals Recent Developments
    Table 174. Research Programs/Design for This Report
    Table 175. Key Data Information from Secondary Sources
    Table 176. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Primary Sclerosing Cholangitis Treatment Market Share by Type: 2023 VS 2030
    Figure 3. Liver Transplantation Operation Features
    Figure 4. UDCA Drugs Features
    Figure 5. PSC Drugs Features
    Figure 6. Global Primary Sclerosing Cholangitis Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Primary Sclerosing Cholangitis Treatment Market Share by Application: 2023 VS 2030
    Figure 8. Hospital Case Studies
    Figure 9. Clinics Case Studies
    Figure 10. Other Case Studies
    Figure 11. Primary Sclerosing Cholangitis Treatment Report Years Considered
    Figure 12. Global Primary Sclerosing Cholangitis Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 13. Global Primary Sclerosing Cholangitis Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Primary Sclerosing Cholangitis Treatment Market Share by Region: 2023 VS 2030
    Figure 15. Global Primary Sclerosing Cholangitis Treatment Market Share by Players in 2023
    Figure 16. Global Top Primary Sclerosing Cholangitis Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Sclerosing Cholangitis Treatment as of 2023)
    Figure 17. The Top 10 and 5 Players Market Share by Primary Sclerosing Cholangitis Treatment Revenue in 2023
    Figure 18. North America Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 19. North America Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
    Figure 20. North America Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
    Figure 21. North America Primary Sclerosing Cholangitis Treatment Market Share by Country (2019-2030)
    Figure 22. United States Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Canada Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Europe Primary Sclerosing Cholangitis Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 25. Europe Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
    Figure 26. Europe Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
    Figure 27. Europe Primary Sclerosing Cholangitis Treatment Market Share by Country (2019-2030)
    Figure 28. Germany Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. France Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. U.K. Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Italy Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Russia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Nordic Countries Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. China Primary Sclerosing Cholangitis Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 35. China Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
    Figure 36. China Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
    Figure 37. Asia Primary Sclerosing Cholangitis Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 38. Asia Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
    Figure 39. Asia Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
    Figure 40. Asia Primary Sclerosing Cholangitis Treatment Market Share by Region (2019-2030)
    Figure 41. Japan Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. South Korea Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. China Taiwan Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. India Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Australia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 48. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Share by Type (2019-2030)
    Figure 49. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Share by Application (2019-2030)
    Figure 50. Middle East, Africa, and Latin America Primary Sclerosing Cholangitis Treatment Market Share by Country (2019-2030)
    Figure 51. Brazil Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Mexico Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Turkey Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Saudi Arabia Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Israel Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. GCC Countries Primary Sclerosing Cholangitis Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. Allergan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 58. Glenmark Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 59. Impax Laboratories Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 60. Mylan Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 61. Teva Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 62. Dr. Falk Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 63. Daewoong Pharmaceutical Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 64. Epic Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 65. Mitsubishi Tanabe Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 66. Lannett Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 67. Bruschettini Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 68. Shanghai Pharma Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 69. Grindeks Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 70. Acorda Therapeutics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 71. Gilead Sciences Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 72. Intercept Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 73. Shire Plc Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 74. NGM Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 75. Conatus Pharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 76. Durect Corporation Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 77. Sirnaomics Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 78. Shenzhen HighTide Biopharmaceuticals Revenue Growth Rate in Primary Sclerosing Cholangitis Treatment Business (2019-2024)
    Figure 79. Bottom-up and Top-down Approaches for This Report
    Figure 80. Data Triangulation
    Figure 81. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Global Primary Biliary Cholangitis Therapeutics Market Insights Forecast to 2030
Global Primary Biliary Cirrhosis Drug Market Research Report 2024
Global Biliary Tract Disorder Treatment Market Insights Forecast to 2030
Global Systemic Sclerosis Treatments Market Research Report 2024
Global Scleroderma Therapeutics Market Insights Forecast to 2030
Global Wilsons Disease Treatment Market Research Report 2024
Global Non Alcoholic Steatohepatitis Treatment Market Research Report 2025
Global Ursodeoxycholic Acid Drug Market Research Report 2024
Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Digestive Distress Treatment Market Research Report 2024
Global Choledocholithiasis Treatment Market Research Report 2024
Global Pancreatic and Bile Duct Cancer Drug Market Insights Forecast to 2030
Liver Diseases Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Primary Sclerosing Cholangitis PSC Market Research Report 2024
Global Primary Biliary Cholangitis Treatment Market Research Report 2024
Progressive Familial Intrahepatic Cholestasis Cholestyramine Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Systemic Scleroderma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Multiple Sclerosis Drugs Treatment Market Insights Forecast to 2030
Chronic Liver Diseases Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Psoriasis Therapeutics Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions